The European Training Network (ETN) Synaptic Dysfunction in Alzheimer Disease (SyDAD) is a research school sponsored by Horizon 2020 Marie Sklodowska Curie Actions that supports 15 Early Stage Researchers (ESRs).

SyDAD is an interdisciplinary PhD programme including an innovative research programme with cutting edge methodology, an excellent training programme, international exchanges and a translational and collaborative orientation.

The aims of SyDAD are:

1. To train 15 Early Stage Researchers to a new generation of researchers with an innovative mind-set and full understanding of the requirements of academia, pharmaceutical companies, the clinics and the societal challenges.

2. To, through a collaborative research programme, elucidate how the different pathways underlying synaptic dysfunction in Alzheimer Disease relate to each other and to identify novel pharmaceutical targets and to elaborate a drug discovery platform for future implementation of the results.

Participating Organisations

SyDAD consists of four academic organisations and two pharmaceutical companies that all will employ PhD students:

Karolinska Institutet



Prof Bengt Winblad

Site-responsible scientist and Project Manager

Assoc Prof Susanne Frykman

University of Bordeaux


Site-responsible scientist:

Prof Christophe Mulle

University of Milano


Site-responsible scientist:

Prof Monica di Luca

Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)

Site-responsible scientist:

Prof Eckhard Mandelkow

Janssen Pharmaceuticals

Site-responsible scientist

Dr Juan D Pita Almenar

Axon Neuroscience

Site-responsible scientist

Prof Michal Novak

In addition, collaborations, secondments and training will also take place at: